10-Q: Ekso Bionics Q3 2025: Revenue Up, Net Loss Narrows Amid Strategic Shifts

Ekso Bionics Holdings, Inc. reported a 2% revenue increase and a significant reduction in net loss for Q3 2025, while addressing going concern doubts and pursuing strategic transactions.

Summary

• Revenue for the three months ended September 30, 2025, increased by $0.1 million, or 2%, to $4.227 million compared to $4.129 million in the same period of 2024.
• Net loss for the three months ended September 30, 2025, significantly decreased by 31% to $1.421 million, compared to $2.072 million in the prior year period.
• Gross profit for Q3 2025 rose by $0.3 million, or 15%, to $2.549 million, with gross margin improving to 60% from 53% in Q3 2024.
• For the nine months ended September 30, 2025, revenue decreased by $3.2 million, or 25%, to $9.659 million compared to $12.835 million in the same period of 2024.
• Net loss for the nine months ended September 30, 2025, decreased by 11% to $7.021 million, compared to $7.917 million in the prior year period.
• The company had an accumulated deficit of $257.722 million and cash on hand of $2.722 million as of September 30, 2025.
• Management has concluded that substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the financial statements' issuance date, with current cash expected to fund operations into Q1 2026.
• A 1-for-15 reverse stock split was effected on June 2, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• The company paid off its $2.0 million secured term loan with Banc of California on September 12, 2025, using restricted cash.
• A new secured promissory note for up to $2.0 million was entered into with B. Riley Commercial Capital, LLC on September 12, 2025, maturing on September 14, 2026, or upon a Qualified Financing, bearing 10% interest and a 10% exit fee.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the explicit 'going concern' warning, significant year-to-date revenue decline, and decreasing working capital. While Q3 showed some operational improvements (revenue growth, reduced net loss, improved gross margin), these are overshadowed by the fundamental liquidity challenges and reliance on future capital raises. The strategic initiatives and CMS reimbursement progress offer some long-term potential but do not alleviate immediate concerns.

Positives

• Q3 2025 revenue increased by 2% year-over-year, driven by higher Enterprise Health device sales in the Americas.
• Gross profit for Q3 2025 increased by 15%, and gross margin improved to 60% from 53% in Q3 2024, primarily due to higher-margin device sales and improved service margins.
• Net loss for Q3 2025 significantly narrowed by 31% to $1.421 million, reflecting improved operational efficiency.
• Operating expenses decreased across sales and marketing (-25%), research and development (-29%), and general and administrative (-10%) for Q3 2025, partly due to Employee Retention Credit (ERC) and headcount reductions.
• Net cash used in operating activities decreased by $0.9 million, or 11%, for the nine months ended September 30, 2025, compared to the same period in 2024, due to cost savings and ERC receipt.
• CMS approved a payment level of approximately $91,000 for Medicare reimbursement of the Ekso Indego Personal device, effective April 1, 2024, with initial claims successfully reimbursed.
• The company received $523,000 in Employee Retention Credits (ERC) in August 2025, which offset payroll expenses and generated interest income.

Negatives

• Total revenue for the nine months ended September 30, 2025, decreased by 25% to $9.659 million, primarily due to lower Enterprise Health device sales in the EMEA region.
• The company incurred significant operating losses and negative cash flows from operations since inception, with an accumulated deficit of $257.722 million as of September 30, 2025.
• Working capital decreased to $5.9 million as of September 30, 2025, from $11.3 million as of December 31, 2024, primarily due to lower cash and accounts receivable balances.
• Cash on hand decreased to $2.722 million as of September 30, 2025, from $4.493 million as of December 31, 2024.
• Loss from operations for the nine months ended September 30, 2025, increased by 7% to $8.817 million compared to $8.230 million in the prior year period.
• General and administrative expenses increased by 5% for the nine months ended September 30, 2025, due to higher legal and audit costs and severance expense.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least 12 months from the date of issuance of the financial statements, with cash expected to fund operations only into Q1 2026.
• Inability to obtain adequate financing on acceptable terms or in sufficient amounts to fund operations and develop technology.
• Inability to generate sufficient cash flow to service debt obligations.
• Dependence on obtaining and maintaining regulatory approval to market medical devices.
• Challenges in completing clinical trials on a timely basis or ensuring they are sufficient for product commercialization.
• Difficulty in effectively marketing and selling products, expanding the business, and achieving broad customer adoption.
• Existing or increased competition in the exoskeleton market.
• Inability to sell additional units or recognize expected margins and revenue using the reimbursement code for the Ekso Indego Personal device with CMS.
• Delays or cancellations in CMS reimbursement decisions, or material changes to reimbursement levels, could diminish sales in the Personal Health market.
• Inability to obtain insurance coverage beyond CMS and VA for products.
• Inability to obtain additional indications of use for devices.
• Rapid changes in technological solutions available to target markets.
• Volatility in business due to long and variable sales cycles, impacting quarterly results.
• Changes to domestic or international sales and operations.
• Inability to obtain or maintain patent protection for intellectual property, or challenges related to third-party intellectual property rights.
• Significant government regulation of medical devices and the healthcare industry.
• Inability to receive regulatory clearance from government authorities, including any conditions or restrictions.
• Customers' ability to get third-party reimbursement for products and services, and the company's ability to manage the complex reimbursement process.
• Potential for products to be subject to voluntary or involuntary recall.
• Product liability insurance may not adequately cover potential claims.
• Warranty claims and accelerated maintenance programs resulting in additional operating costs.
• Failure to implement business plans or strategies, including reliance on CMS reimbursements as a significant revenue source.
• Inability to successfully consummate acquisitions or dispositions, including strategic transactions, on acceptable terms and integrate them.
• Early termination of leases, difficulty filling vacancies, or negotiating improved lease terms.
• Inability to retain or attract key employees.
• Impacts of foreign currency price fluctuations.
• Overall economic and market conditions, including an increasingly inflationary environment and price-based competition.
• Disruption of federal funding for customers due to budget cuts or shifting policy priorities.
• Material impairments in the value of intangible assets, including developed technology and trade name, which could negatively affect operating results (e.g., potential impairment for HMC assets in Q4 2025).
• Dilution from future issuances of equity securities, including in strategic transactions, future financings, compensatory equity awards, and warrant exercises.
• Inability to reduce the cost to manufacture or service products as planned.
• Shortages in materials and supply chain disruptions, including from trade policies and tariffs.
• International sales being subject to factors outside of the company's control, such as protectionist laws, regulatory differences, and political instability.
• Shutdowns of the U.S. federal government could materially impair business and financial condition by delaying regulatory reviews or access to public markets.

Future Outlook

Management expects to generate operating losses and negative operating cash flows in the future and will require additional funding to support planned operations, with current cash funding operations into the first quarter of 2026. The company is pursuing strategic partnerships, delaying or abandoning certain product development projects, implementing cost reduction efforts, and refocusing sales to accelerate revenue growth. General commercialization of the Nomad device is expected in 2026, subject to clinical and patient feedback. The company is also exploring one or more strategic transactions, which may include acquiring a new business line or selling its current business, with any such transaction likely requiring stockholder approval and involving substantial equity issuance.

Management Comments

• Management intends to raise funds through one or more financings in the near term to meet cash requirements for the next 12 months.
• Management is simultaneously pursuing strategic partnerships, delaying or abandoning certain product development projects, cost reduction efforts for products, and refocusing sales efforts to accelerate revenue growth above historical results.
• We have concluded the likelihood that our plan to successfully reduce expenses to align with our available cash, while reasonably possible, is less than probable.
• Management currently estimates that the company's cash will fund its operations into the first quarter of 2026.
• We anticipate that many of the over 50 individuals believed to qualify for reimbursement for the Ekso Indego Personal device will have their claims submitted to CMS by our partners from time to time over the next 12 months.
• We expect our processes and procedures for CMS reimbursement submissions to continue to be refined as we work to scale up this sales channel over time.
• Given this ramp, we expect the majority of our revenue in 2025 will continue to come from Enterprise Health sales, but with Personal Health product sales contributing more quarter over quarter.
• We believe that sales of our Personal Health products have the potential to be a significant growth driver as we work to gain coverage by other insurance providers, expand the products' indications of use beyond SCI and optimize our reimbursement submission processes.
• Subject to clinical and patient feedback from clinical trials, we expect to begin the general commercialization process for Nomad in 2026.
• There can be no assurances that any strategic transaction will occur, and the company expects to continue executing on its growth strategy during this process.

Industry Context

The company operates in the healthcare exoskeleton market, which is influenced by factors such as awareness of robotic exoskeleton rehabilitation, levels of third-party reimbursements (including Medicare and private insurers), overall economic growth, and general business activity. The market faces increasing price-based competition, particularly for major capital expenditure items like the EksoNR and Ekso Indego Therapy devices, which have lengthy sales cycles. The approval of Medicare reimbursement for the Ekso Indego Personal device creates a significant opportunity to serve a larger U.S. patient population with spinal cord injury (SCI), aligning with broader trends towards expanding access to advanced rehabilitation technologies. However, operating within the CMS reimbursement environment is new for the company, requiring refinement of processes and development of channel partnerships with Durable Medical Equipment (DME) and Orthotics & Prosthetics (O&P) suppliers. The industry is also subject to federal funding and policy changes, which can disrupt customer purchasing power, and foreign currency fluctuations impact international sales.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to assess the company's performance against global benchmarks. However, the company's focus on expanding its Personal Health market through CMS reimbursement for the Ekso Indego Personal device aligns with a broader industry trend of seeking to make advanced medical devices more accessible to individual users outside of clinical settings.
• The reported gross margin of 60% for Q3 2025 and 54% for YTD 2025, while improved from prior periods, would need to be benchmarked against other medical device manufacturers, particularly those in specialized rehabilitation robotics, to determine competitiveness. The filing indicates these improvements are partly due to high-margin device sales and service improvements, suggesting a positive internal trend.
• The company's ongoing operating losses and 'going concern' warning are significant deviations from the financial stability expected of established industry leaders and indicate a need for substantial operational improvement or external capital compared to profitable peers in the medical technology sector.

Corporate Governance

Legal Proceedings

• The company is subject to various legal matters arising in the ordinary course of business. Management believes the resolution of such matters will not have a material adverse effect on the condensed consolidated financial statements.

Related Party Transactions

• There were no related party transactions during the nine months ended September 30, 2025. A previous settlement agreement with an entity affiliated with a Board member, totaling $325,000, was fully paid in April 2024.

Stakeholder Impact

• **Shareholders**: Face significant risk of dilution from future equity issuances and potential loss of investment due to the 'going concern' uncertainty. The reverse stock split aimed to maintain Nasdaq listing, but the underlying financial challenges persist.
• **Employees**: Benefit from the 401(k) plan matching contributions and stock-based compensation, but potential cost reduction efforts and strategic shifts could impact employment stability or future compensation structures.
• **Customers**: May experience continued product availability and support, particularly with efforts to accelerate revenue growth and refine reimbursement processes for devices like Ekso Indego Personal. However, federal funding cuts could impact certain institutional customers' purchasing ability.
• **Suppliers**: Subject to purchase obligations totaling $534,000 expected within one year, indicating ongoing business relationships, but the company's liquidity challenges could pose risks to timely payments if not adequately addressed.
• **Creditors**: The B. Riley Promissory Note provides a secured term loan, and the payoff of the BoC Term Loan reduces one debt obligation, but the overall financial health and 'going concern' status present elevated credit risk.

Next Steps

• Raise additional funds through one or more financings to meet cash requirements for the next 12 months.
• Pursue strategic partnerships to support operations and growth.
• Delay or abandon certain product development projects to conserve cash.
• Implement cost reduction efforts for products.
• Refocus sales efforts to accelerate revenue growth.
• Continue to refine and improve candidate screening and submission documentation for CMS reimbursement of the Ekso Indego Personal device.
• Develop and grow channel partner programs with Orthotics & Prosthetics (O&P) and Durable Medical Equipment (DME) suppliers for the Personal Health market.
• Seek insurance coverage beyond CMS for Personal Health products.
• Seek additional indications of use for products beyond spinal cord injury (SCI).
• Begin general commercialization process for the Nomad device in 2026, subject to clinical and patient feedback.
• Continue exploring one or more strategic transactions, which may involve an acquisition or sale of business lines.

Key Dates

Recommendation

A 'Hold' recommendation is appropriate given the mixed signals and high uncertainty. While the company demonstrated improved operational performance in Q3 2025 with increased revenue, better gross margins, and a reduced net loss, the significant year-to-date revenue decline and the explicit 'substantial doubt about our ability to continue as a going concern' are major red flags. The company's reliance on future capital raises and the ongoing challenges in scaling the Personal Health market, despite CMS reimbursement, indicate a precarious financial position. A seasoned investor would acknowledge the potential upside from strategic initiatives and market expansion but would also be highly cautious due to the severe liquidity constraints and the fundamental going concern risk. Monitoring the success of future financing efforts and the execution of strategic transactions will be critical before considering a 'Buy' or 'Sell' position.

Keywords

Exoskeleton, Bionics, Medical Devices, Rehabilitation, Spinal Cord Injury, Acquired Brain Injury, Multiple Sclerosis, Robotics, Healthcare Technology, Nasdaq, SEC Filing, 10-Q, EksoNR, Ekso Indego Personal, CMS Reimbursement, Going Concern, Capital Raise, Strategic Transactions, Biotechnology